Bacterial Conjunctivitis

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2010 Dec 29

PMID 21188158

Citations 3

Authors

Cindy Hutnik

Mohammad H Mohammad-Shahi

Affiliations

Soon will be listed here.

Abstract

Clinical Question: What is the best treatment for bacterial conjunctivitis?

Results: Topical antibiotics expedite recovery from bacterial conjunctivitis. The choice of antibiotic usually does not affect outcome.

Implementation: Recognition of key distinguishing features of bacterial conjunctivitis Pitfalls that can be recognized in the history and physical examinationChoice of antibioticWhen to refer for specialist treatment.

Citing Articles

Acute Conjunctivitis among Patients Visiting the Outpatient Department of Ophthalmology in a Tertiary Care Centre.

Shrestha R, Rijal R, Kausar N, Shrestha O, Rajkarnikar S, Chaudhary R JNMA J Nepal Med Assoc. 2024; 62(269):24-26.

PMID: 38410017 PMC: 10924492. DOI: 10.31729/jnma.8391.

Ocular redness - I: Etiology, pathogenesis, and assessment of conjunctival hyperemia.

Singh R, Liu L, Anchouche S, Yung A, Mittal S, Blanco T Ocul Surf. 2021; 21:134-144.

PMID: 34010701 PMC: 8328962. DOI: 10.1016/j.jtos.2021.05.003.

Antibacterial effects of antibiotics and cell-free preparations of probiotics against and associated with conjunctivitis.

Mohamed S, Elmohamady M, Abdelrahman S, Amer M, Abdelhamid A Saudi Pharm J. 2021; 28(12):1558-1565.

PMID: 33424249 PMC: 7783109. DOI: 10.1016/j.jsps.2020.10.002.

References

Granet D, Dorfman M, Stroman D, Cockrum P . A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2008; 45(6):340-9. DOI: 10.3928/01913913-20081101-07. View

Tepedino M, Heller W, Usner D, Brunner L, Morris T, Haas W . Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009; 25(5):1159-69. DOI: 10.1185/03007990902837919. View

Chisari G, Sanfilippo M, Reibaldi M . [Treatment of bacterial conjuntivitis with topical ciprofloxacin and norfloxacin: a comparative study]. Infez Med. 2003; 11(1):25-30. View

Papa V, Aragona P, Scuderi A, Blanco A, Zola P, Di B . Treatment of acute bacterial conjunctivitis with topical netilmicin. Cornea. 2002; 21(1):43-7. DOI: 10.1097/00003226-200201000-00010. View

Lichtenstein S, Rinehart M . Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS. 2003; 7(5):317-24. DOI: 10.1016/s1091-8531(03)00168-x. View

Normann E, Bakken O, Peltola J, Andreasson B, Buhl S, Sigg P . Treatment of acute neonatal bacterial conjunctivitis: a comparison of fucidic acid to chloramphenicol eye drops. Acta Ophthalmol Scand. 2002; 80(2):183-7. DOI: 10.1034/j.1600-0420.2002.800212.x. View

LEIBOWITZ H . Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991; 112(4 Suppl):29S-33S. View

Jackson W, Low D, Dattani D, Whitsitt P, Leeder R, MacDougall R . Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol. 2002; 37(4):228-37; discussion 237. DOI: 10.1016/s0008-4182(02)80114-4. View

Everitt H, Little P, Smith P . A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ. 2006; 333(7563):321. PMC: 1539078. DOI: 10.1136/bmj.38891.551088.7C. View

10.

Adenis J, Colin J, VERIN P, Saint-Blancat P, Malet F . Ciprofloxacin ophthalmic solution versus rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis. Eur J Ophthalmol. 1995; 5(2):82-7. DOI: 10.1177/112067219500500203. View

11.

Karpecki P, DePaolis M, Hunter J, White E, Rigel L, Brunner L . Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009; 31(3):514-26. DOI: 10.1016/j.clinthera.2009.03.010. View

12.

Schwab I, Friedlaender M, McCulley J, Lichtenstein S, Moran C . A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology. 2003; 110(3):457-65. DOI: 10.1016/S0161-6420(02)01894-8. View

13.

Rose P, Harnden A, Brueggemann A, Perera R, Sheikh A, Crook D . Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet. 2005; 366(9479):37-43. DOI: 10.1016/S0140-6736(05)66709-8. View

14.

Kernt K, Martinez M, Bertin D, International Tobrex X Group Eu G, Stroman D, Cupp G . A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis. Eur J Ophthalmol. 2017; 15(5):541-549. DOI: 10.5301/EJO.2008.993. View

15.

Szaflik J, Szaflik J, Kaminska A . Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Eur J Ophthalmol. 2009; 19(1):1-9. DOI: 10.1177/112067210901900101. View

16.

Denis F, Chaumeil C, Goldschmidt P, Delval L, Pouliquen P, Cochereau I . Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. Eur J Ophthalmol. 2008; 18(6):858-68. DOI: 10.1177/112067210801800602. View

17.

Cochereau I, Meddeb-Ouertani A, Khairallah M, Amraoui A, Zaghloul K, Pop M . 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol. 2006; 91(4):465-9. PMC: 1994738. DOI: 10.1136/bjo.2006.103556. View

18.

Milazzo G, Papa V, Carstocea B, Chercota G, Rodica P, Gafencu O . Topical netilmicin compared with tobramycin in the treatment of external ocular infection. Int J Clin Pharmacol Ther. 1999; 37(5):243-8. View

19.

FRIEDLAENDER M . Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infection. CLAO J. 1998; 24(1):48-51. View

20.

Protzko E, Bowman L, Abelson M, Shapiro A . Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007; 48(8):3425-9. DOI: 10.1167/iovs.06-1413. View